ClinicalTrials.gov record
Completed Phase 4 Interventional

Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US

ClinicalTrials.gov ID: NCT00847483

Public ClinicalTrials.gov record NCT00847483. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 11:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Comparison of Latanoprost (Xalatan) With Travoprost (Travatan) and Bimatoprost (Lumigan) in Patients With Elevated Intraocular Pressure. A Twelve-week, Masked Evaluator, Phase IV, Multicenter Study in the United States. (Xalatan vs Travatan vs Lumigan).

Study identification

NCT ID
NCT00847483
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Enrollment
375 participants

Conditions and interventions

Interventions

  • Bimatoprost .03% sterile ophthalmic solution Drug
  • Travoprost 004% sterile ophthalmic solution Drug
  • latanoprost 0.005% ophthalmic solution Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2001
Primary completion
Jul 31, 2002
Completion
Jul 31, 2002
Last update posted
Feb 1, 2021

2002

United States locations

U.S. sites
40
U.S. states
22
U.S. cities
34
Facility City State ZIP Site status
Pfizer Investigational Site Bellflower California 90706
Pfizer Investigational Site Inglewood California 90301
Pfizer Investigational Site San Diego California 92103
Pfizer Investigational Site San Diego California 92116
Pfizer Investigational Site San Francisco California 94115
Pfizer Investigational Site Gainesville Florida 32610
Pfizer Investigational Site Lakeland Florida 33805
Pfizer Investigational Site Ormond Beach Florida 32174
Pfizer Investigational Site Atlanta Georgia 30339
Pfizer Investigational Site Bloomingdale Illinois 60108
Pfizer Investigational Site Evansville Indiana 47710
Pfizer Investigational Site Louisville Kentucky 40207
Pfizer Investigational Site Louisville Kentucky 40217
Pfizer Investigational Site Shreveport Louisiana 771104
Pfizer Investigational Site Bangor Maine 04401
Pfizer Investigational Site Kansas City Missouri 64111
Pfizer Investigational Site Kansas City Missouri 64114
Pfizer Investigational Site Omaha Nebraska 68198-5540
Pfizer Investigational Site Las Vegas Nevada 89104
Pfizer Investigational Site Bloomfield New Jersey 07003
Pfizer Investigational Site Willingboro New Jersey 08046
Pfizer Investigational Site Charlotte North Carolina 28210
Pfizer Investigational Site Winston-Salem North Carolina 27103
Pfizer Investigational Site Streetsboro Ohio 44241
Pfizer Investigational Site Oklahoma City Oklahoma 73104
Pfizer Investigational Site Tulsa Oklahoma 74104
Pfizer Investigational Site Pittsburgh Pennsylvania 15224
Pfizer Investigational Site Charleston South Carolina 29412
Pfizer Investigational Site Charleston South Carolina 29414
Pfizer Investigational Site Charleston South Carolina 29425
Pfizer Investigational Site Maryville Tennessee 37803
Pfizer Investigational Site Memphis Tennessee 38119
Pfizer Investigational Site Dallas Texas 75231
Pfizer Investigational Site El Paso Texas 79902
Pfizer Investigational Site Houston Texas 77025
Pfizer Investigational Site Layton Utah 84041
Pfizer Investigational Site Norfolk Virginia 23505
Pfizer Investigational Site Norfolk Virginia 23507
Pfizer Investigational Site Virginia Beach Virginia 23456
Pfizer Investigational Site Wenatchee Washington 98801

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00847483, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 1, 2021 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00847483 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →